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Abstract
Heterozygous germ-line variants of DNA mismatch repair (MMR) genes predispose individuals to hereditary non-polyposis
colorectal cancer. Several independent reports have shown that individuals constitutionally homozygous for MMR allelic variants
develop early onset hematological malignancies often associated to features of neurofibromatosis type 1 (NF1) syndrome. The
genetic mechanism of NF1 associated to MMR gene deficiency is not fully known. We report here that a child with this form of
NF1 displays a heterozygous NF1 gene mutation (c.3721C > T), in addition to a homozygous MLH1 gene mutation (c.676C > T)
leading to a truncated MLH1 protein (p.R226X). The parents did not display NF1 features nor the NF1 mutation. This new NF1
gene mutation is recurrent and predicts a truncated neurofibromin (p.R1241X) lacking its GTPase activating function, as well as all
C-terminally located functional domains. Our findings suggest that NF1 disease observed in individuals homozygous for deleterious
MMR variants may be due to a concomitant NF1 gene mutation. The presence of both homozygous MLH1 and heterozygous NF1
mutation in the child studied here also provides a mechanistic explanation for early onset malignancies that are observed in affected
individuals. It also provides a model for cooperation between genetic alterations in human carcinogenesis.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
The classical neurofibromatosis type 1 (NF1) syn-
drome, also known as von-Recklinghausen’s disease or
peripheral neurofibromatosis, is an autosomal dominant
disorder linked to NF1 gene mutations of which 50%
are new mutations [1]. In 1999, Ricciardone et al. [2]
and Wang et al. [3] have identified a novel form of NF1
syndrome that is associated with homozygous germ-line
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utations of MLH1 gene in two independent families.
hese initial observations have now been confirmed by
thers and extended to biallelic mutations of other DNA
ismatch repair (MMR) genes, including MSH2, MSH6
nd PMS2 [4–8]. Eight children (five girls, three boys)
omozygous for MMR gene variants have been inde-
endently described [reviewed in ref. 7]. All of these
hildren present with clinical features of NF1 that are
ften associated with hematological malignancies. Four
f the families have been initially identified as heredi-
ary non-polyposis colorectal cancer (HNPCC) families
2–4,6]. The fifth case did not have a familial history of
ancer [5]. MLH1 and MSH2 genes were mutated in four
nd one families, respectively. Homozygous mutations
f MLH1 gene were demonstrated in five, and suspected
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n two children. The remaining child had a homozygous
SH2 gene mutation. The novel form of NF1 is asso-
iated with early onset childhood malignancies, most
f which are either leukemias or lymphomas [2,3,5]. All
he parents of the affected children were heterozygous for
he same MMR gene mutation, some of whom had devel-
ped colorectal cancers at the time of diagnosis, but none
isplayed NF1 disease and/or childhood malignancies.
NF1 with early onset childhood malignancies
bserved in these children is specifically associated
ith a homozygous MMR gene mutation. However, this
ssociation does not necessarily mean that homozygous
MR gene mutation is directly implicated in the devel-
pment of this disease syndrome. NF1 which is not a
nown component of HNPCC syndrome [8] is not asso-
iated with MMR gene mutation [3]. However, it remains
ossible that a concomitant mutation affecting NF1 gene
s involved in this disease.
In this report, we further studied the archival
enomic DNAs from a Turkish family that we have
lready reported for the status of MLH1 [2]. In this
NPCC family, displaying a germ-line mutation in
LH1 (p.R226X), there was a consanguineous mar-
iage between two members, both heterozygous for the
utation (Fig. 1). All three children born from this mar-
iage developed NF1 disease associated with early onset
ematological malignancies and a homozygous MLH1
utation had been found in at least two siblings. The
other and father were heterozygous for MLH1 muta-
ig. 1. Simplified pedigree of the HNPCC kindred TF3 with MLH1
ene mutation. Filled symbols indicate colon cancer; shaded symbols
ndicate neurofibromatosis type 1. Numbers below symbols indicate
ge at diagnosis. (±): Heterozygous MLH1 mutation. The TF3 kindred
as described previously [4]. Briefly, the focus of this investigation,
hild IV-4, developed atypical chronic myeloid leukemia at 12 months
nd displayed clinical signs of type I neurofibromatosis. Two siblings,
V-3 and IV-2, also developed leukemia/lymphoma and died in early
hildhood. Clinical signs of neurofibromatosis were confirmed in the
ibling IV-3. The parents (III-5 and III-6) were both afflicted with
olorectal cancer at an early age, 26 and 33 years old, respectively.
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ion and developed colorectal cancers at 26 and 33 years,
espectively, but they did not display NF1 clinical fea-
ures nor did they develop hematological malignancy
2]. We report here on the identification of a heterozy-
ous NF1 gene mutation in the archival DNA samples
rom child IV-4 who developed atypical chronic myeloid
eukemia at 12 months, and displayed NF1 features with
afe´ au lait spots and fibromatous skin tumors [2].
. Materials and methods
.1. Patients and DNA samples
Informed consent was obtained from all participants in the
tudy. The TF3 kindred was described previously [2]. Briefly,
he focus of this investigation, child IV-4, developed atypical
hronic myeloid leukemia at 12 months and displayed NF1 fea-
ures with more than 10 abdominal cafe´ au lait spots (≥15 mm)
nd two fibromatous skin tumors. Two siblings, IV-3 and IV-2,
lso developed leukemia/lymphoma and died in early child-
ood. Clinical signs of neurofibromatosis were confirmed in the
ibling IV-3. The parents (III-5 and III-6) were both afflicted
ith colorectal cancer at an early age, 26 and 33 years old,
espectively. Blood samples from the parents were collected in
ubes containing EDTA. The DNAs of wt, FIII-6, MIII-5 and
hild IV-4 has been extracted from freshly collected blood sam-
les and was then stored at −80 ◦C. The DNA for sibling IV-3
as been extracted from an archival bone marrow smear. Dif-
erential blood counting of the child IV-4 at the time the blood
as drawn for DNA analysis displayed 14% blast cells [2].
.2. PCR and SSCP
NF1 exons 16, 21, 22, 23-2 and 23a were amplified using
pecific primers that were described previously [9]. PCR
as carried out in 25l reaction volumes containing 1.5 mM
gCl2, 10 pmoles of each primer, 200M dNTP mix and 1
nitTaqDNA polymerase (Fermentas) and 50–100 ng genomic
NA. PCR conditions were an initial denaturation step at 95 ◦C
or 5 min followed by 30 cycles of 30 s at 95 ◦C, 30 s at 55 ◦C,
0 s at 72 ◦C followed by a 10 min final extension step. Quality
f PCR products was verified by agarose gel electrophoresis.
or single strand conformation polymorphism (SSCP) anal-
sis, PCR was done in the presence of 1Ci [32P] dCTP
Amersham) per reaction and radiolabeled PCR products were
enatured using SSCP gel loading buffer (95% formamide
Sigma), 10 mM NaOH (Carlo Erba), 0.25% bromophenol blue
Sigma) and 0.25% xylene cyanol (Sigma)). The DNA solution
as heated at 95 ◦C for 2 min and kept on ice for at least 10 min
efore loading onto a 6% [75:1] acrylamide gel on the EC 160
pparatus. Electrophoresis was performed at 45 W constant
◦ower at 4 C for 8 h. Phosphoimaging was performed using the
olecular Imager® System, GS-525 (Bio-Rad). The dried gel
as placed into the cassette and a clean, erased screen was then
laced over the gel. After exposure, the screen was scanned and
he image was captured using Multi-Analyst software.
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2.3. DNA sequence analysis
Sequence analysis was performed using DYEnamic ET
Terminator cycle sequencing kit (Amersham) according to
the recommended protocol with the following modifications:
annealing temperature was 59 ◦C, and only 3 pmoles of primer
were used for the reverse primer reaction. Automated sequence
analysis was performed on the 310 Genetic Analyzer (ABI;
Perkin-Elmer) as recommended by the manufacturer.
2.4. TaqI restriction digestion
Genomic DNAs from parents (MIII-5 and FIII-6), child
IV-4 and a wild-type control were used to amplify NF1 exon
22. The amplified products were analyzed by electrophoresis,
and normalized by densitometric analysis using the BioRad
Multi-Analyst software. Equal amounts of PCR products were
used for TaqI digestion, which was performed at 65 ◦C under
mineral oil. The restriction digestion products with undigested
controls were resolved on a 4% NuSieve 3:1 agarose (FMC
Bioproducts) prepared in 0.5× TBE, for 3 h at 8 V/cm. Densit-
ometric quantification was performed on the undigested DNA
fragments, the amount of the mutant allele resistant to restric-
tion enzyme digestion was compared to the undigested PCR
product.
3. Results and discussion
Archival genomic DNA from child IV-4 was sub-
jected to a detailed NF1 gene mutation analysis (Fig. 1).
As NF1 is a large gene, we applied a rapid screen-
ing technique based on SSCP analysis of selected NF1
gene regions. The exons that contained microsatellites
and CpG islands within the NF1 GAP-related domain
(NF1-GRD) were targeted initially (Fig. 2).
Following the screening of exons 16, 21, 22, 23-
2 and 23a, we obtained a band-shift with exon 22 in
DNA from child IV-4 that was not present in parental
DNAs. PCR products corresponding to other exons did
not produce band-shifts (data not shown). An indepen-
dently prepared PCR product for exon 22 was then used
for direct DNA sequence analysis. We identified a C
Fig. 2. Schematic representation of NF1 exons used in mutation
screening experiments. NF1 exons selected for analysis were ampli-
fied from genomic DNA, and PCR products were further analyzed by
SSCP and the presence of the mutation was then confirmed by direct
DNA sequence analysis. Vertical lines represent NF1 exons, transpar-
ent rectangle represents NF1-GRD exons, and arrowheads mark exons
selected for analysis. Drawing is not to scale.
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o T transition at nucleotide 3721 of NF1 gene. The
lectropherogram profile obtained displayed both wild-
ype and mutant sequences, suggesting that child IV-4
ad a unique heterozygous NF1 mutation. Both father
nd mother displayed only wild-type NF1 sequence at
his site, indicating that child IV-4 had a new NF1
ene mutation (Fig. 3a). This mutation is predicted to
ause a substitution of arginine 1241 for a stop codon;
p.R1241X) at the protein level. The point mutation
as verified by restriction enzyme digestion with TaqI,
hose restriction site is lost as a consequence of the
to T transition. Restriction enzyme digestion experi-
ents indicated that only 50% of the PCR product from
hild IV-4 was digested with TaqI, clearly confirming
he presence of a heterozygous state in this exon. In con-
rast, PCR products from father, mother as well as from
control sample were completely digested by TaqI, as
xpected from the DNA sequence data (Fig. 3b).
To rule out the possibility of incomplete digestion
rom the mutant allele of child IV-4 sample, we amplified
longer DNA fragment using another intronic primer
ocated 1438 bps upstream of the priming site of exon
2, harboring an additionalTaqI restriction site. The PCR
roducts (1770 bp) from both parents and both siblings
child IV-3 and child IV-4) were digested to completion
ith TaqI, as a result, the presence of the (c.3721C > T)
eterozygous state was confirmed for child IV-4 by
he loss of TaqI recognition site (see supplementary
gure). This mutation was absent from a sister (child
V-3), further confirming that child IV-4 had a new NF1
utation.
Since the initial description of the association of neu-
ofibromatosis features and early onset of childhood
alignancies with homozygous mutations of MLH1
ene [2,3], 14 cases of biallelic mismatch repair gene
utations (mostly homozygous, but also compound het-
rozygous) affecting the MLH1, MSH2, MSH6 or PMS2
enes have been described, as recently reviewed by
andipalliam [8]. These cases are characterized by early
nset hematological malignancies (mean age of diagno-
is: 5.6 years), and gastrointestinal cancers (mean age
f diagnosis: 12.2 years), as well as the distinct clinical
eatures of type I neurofibromatosis [8]. More impor-
antly, such clinical features have not been detected in
he parents of these individuals [8], strongly suggesting
hat this particular form of neurofibromatosis is caused
y mismatch repair deficiency leading to a mutation
f NF1 gene. Several studies provided convincing data
upporting the hypothesis that MMR deficiency and neu-
ofibromatosis may be associated with NF1 mutations.
ang et al. [10] have reported that NF1 gene is often
utated in DNA mismatch repair-deficient cancer cell
212 H. Alotaibi et al. / Mutation Research 637 (2008) 209–214
Fig. 3. Heterozygous NF1 mutation in a MLH1-deficient child with neurofibromatosis type I and early onset leukemia. Genomic DNAs from parents
(MIII-5 and FIII-6), child IV-4 and a wild-type control were used to amplify NF1 exon 22 to be used for DNA sequence analysis and then for
verification by restriction enzyme digestion. (a) A small stretch of the electropherogram flanking the mutation showing the nucleotide sequence
obtained with forward and reverse primers (the left and right panels, respectively). Arrow heads indicate heterozygosity [T/C designated as Y] at
nucleotide 3721. (b) PCR amplified DNA samples were analyzed by electrophoresis, and normalized by densitometric analysis using the BioRad
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ane C IV-4, child IV-4; F III-6, Father; M III-5, Mother; wt DNA, wil
reshly prepared PCR products.
ines, as well as in primary tumors exhibiting microsatel-
ite instability. They have also shown a “mosaic” type of
utation of the murine nf1 gene in 2 of 14 clones gener-
ted from mlh1-deficient mouse embryonic fibroblasts,
roviding additional evidence that NF1 gene may be a
utational target in mismatch repair-deficient cells [10].
oreover, leukemogenesis in nf1 heterozygous mice
as shown to be accelerated by mlh1 deficiency [11].
owever, to our knowledge, there is no previous data
eporting potential NF1 gene mutations in individuals
ith DNA mismatch repair gene mutations [7]. Thus,
he molecular mechanism(s) of neurofibromatosis in
ndividuals with biallelic mutations remained unknown.
ere, we show that blood DNA from a child who devel-
ped atypical chronic myeloid leukemia at 12 months
nd displayed NF1 features with more than 10 abdom-
nal cafe´ au lait spots (>15 mm) and two fibromatous
p
d
a
sestion (lanes with “+” signs) as described in Section 2. The enzyme’s
1C > T mutation will render the site unrecognizable by the enzyme.
ontrol. Data represents experiments repeated at least three times with
kin tumors displays a new c.3721C > T mutation at NF1
ene. This is a recurrent mutation at a predicted CpG
ite, initially reported by Fahsold et al. [12], leading to
severely truncated neurofibromin protein (p.R1241X).
he mutant protein is expected to have lost its nega-
ive regulatory function of ras oncogene because of the
ack of GTPase activating as well as other C-terminally
ocated functional domains [13]. To our knowledge this
s the first demonstration of a NF1 gene mutation in
MMR deficient patient with neurofibromatosis and
arly onset hematological malignancy. Our finding pro-
ides a plausible explanation for the genetic cause of
eurofibromatosis observed in patients displaying this
henotype [8]. Thus, secondary NF1 mutations may pre-
ispose MMR deficient individuals to neurofibromatosis
nd/or early onset malignancies, similar to classical NF1
yndrome [12].
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Currently, the genetic mechanism of NF1 mutation in
MMR deficient individuals is unknown. NF1 is known
as an autosomally dominant condition. About 50% of
cases result from new mutations, and some cases dis-
play germline mosaicism. Most of the new mutations
occur on the paternally derived chromosome, whereas
large deletions are usually of maternal origin [14]. The
C to T mutation observed in the child IV-4 occurred
at a CpG motif, such type of mutations are known to
occur as a result of deamination of methyl cytosine
which would lead to a T:G mismatch which is usually
repaired by MMR system. As this mutation occurred
in a MMR deficient condition, it may be secondary
to this particular condition. It is unclear whether this
mutation occurred post-zygotically in the parental chro-
mosome, or rather somatically in the affected child.
Such mutations appear to occur in NF1 patients as
some of them display a “mosaic” pattern [12,14]. If
the same event took place in the child IV-4, this must
have been a very early embryonic mutation, as the child
already displayed many cafe´-au-lait spots (≥15 mm)
and two fibromatous skin tumors at the age of 12
months, together with leukemia [2]. Although we were
unable to test whether this particular mutation display
“mosaicism”, we favor the hypothesis that the heterozy-
gous NF1 mutation detected in child IV-4 is a very
early somatic mutation that occurred in the embryonic
cells.
The co-existence of a homozygous MMR gene muta-
tion with a tumor suppressor gene mutation (i.e. NF1
mutation) at the individual level is also a new find-
ing. This has been previously suggested as a potential
mechanism involved in cancer predisposition of indi-
viduals carrying constitutional MMR gene mutations
[2,3]. Accordingly, the loss of the wild-type MMR gene
in pre-malignant cells results in genetic instability giv-
ing rise to a high rate of mutations eventually affecting
critical tumor suppressor genes [15]. As already indi-
cated, the NF1 gene appears as a frequent target for
mutations in MMR-deficient cells [10]. Therefore, the
occurrence of the new NF1 mutation identified here may
have been facilitated by DNA mismatch repair deficiency
in body cells due to inherited homozygous MLH1 muta-
tion in the affected child. However, this remains as an
interesting, yet unproven hypothesis in the absence of
a direct evidence for a cause–effect relationship for the
co-occurrence of MLH1 and NF1 gene mutations in the
same individual.Cancer is a multistage process which requires the con-
tribution of different genetic alterations. Mouse models
have been successfully used to study carcinogenic effects
resulting from combinations of genetic alterations. Such
Rrch 637 (2008) 209–214 213
tudies have allowed developing several important con-
epts for tumorigenesis, such as cooperation between
ncogenes, or oncogene-tumor suppressor gene inter-
ctions [16]. However, it is unknown how and to what
xtent such fundamental concepts apply to tumorigen-
sis processes in humans. Our observations provide a
nique opportunity to address this issue. In the child we
tudied here, there was a homozygous MLH1 mutation
nd a heterozygous NF1 mutation. A similar situation
as been created experimentally in mice homozygous
or mlh1 (−/−) and heterozygous nf1 (±) mutations
11]. These double mutant mice displayed accelerated
yeloid leukemogenesis when compared to mice carry-
ng single gene mutations, indicating that two genetic
lterations cooperated for the generation of hemato-
ogical malignancies. In humans with classical NF1
yndrome due to NF1 mutations, hematological malig-
ancies are detected, but only rarely (less than 5%;
17]), suggesting that NF1 mutation alone has a mod-
rate effect on hematological malignancy susceptibility.
n the other hand, hematological malignancies are not
known component of tumors observed in HNPCC
atients with heterozygous DNA mismatch repair gene
utations, including the parents of the child IV-4. In
ontrast, the child IV-4 with MLH1 (−/−)/NF1 (±)
eveloped leukemia at the age of 1 year. Thus, in line
ith the predictions based on data gathered using exper-
mental mice models, multiple genes may also cooperate
n humans for accelerated tumor susceptibility. Child IV-
is not an isolated case; at least a dozen other children
hare exactly the same clinical features of early onset
ematological malignancies and neurofibromatosis [8].
t will be interesting to know whether our gene alteration
ooperation model is a general feature of this particular
yndrome.
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